#South Korea #Seoul #Dementia #Deepson Bio #Neuclare

Deepson Bio Receives Presidential Award at 2025 Korea Invention Patent Exhibition

Deepson Bio Co., Ltd., a pioneering medical technology firm specializing in ultrasound-based treatments for dementia, has been honored with the esteemed Presidential Award at the 2025 Korea Invention Patent Exhibition. This annual event, held in Seoul at the bustling COEX center, serves as South Korea's premier venue for recognizing innovations in intellectual property, drawing participation from numerous institutions and innovators.

During the exhibition, which occurred in December 2025, Deepson Bio stood out among a plethora of participants. The company was celebrated not only for its brilliant research but also for its commitment to translating that research into practical applications that can revolutionize dementia treatment. The Presidential Award, the highest accolade bestowed at the event, is awarded to only one organization each year, making this accomplishment a significant milestone for Deepson Bio and its team.

The winning technology revolves around an innovative ultrasound device aimed at enhancing the clearance of metabolic waste from the brain's lymphatic system. Titled "Ultrasound devices for promoting waste product emissions in the brain lymphatic system using interactive ultrasound irradiation by multiple transducers" (Patent No. 10-2317379), this groundbreaking method utilizes low-frequency ultrasound to assist in removing substances like beta-amyloid, which are implicated in dementia.

Since its foundation in 2018, Deepson Bio has dedicated itself to developing non-invasive solutions for neurological ailments. The company's flagship device, known as 'Neuclare,' represents a significant leap forward in the treatment of dementia. The device enables the improvement of cerebrospinal fluid flow and the clearance of unwanted waste, thereby addressing the pressing needs presented by neurodegenerative diseases. Unlike traditional therapies that may disrupt the blood-brain barrier or trigger adverse side effects, Neuclare's ultrasound method presents a safer alternative for patients.

Donghyuk Lee, CEO of Deepson Bio, expressed pride in receiving the Presidential Award, stating, "This recognition is a testament to the innovative potential of ultrasound-based devices in dementia care. As we prepare for the next steps of clinical development for Neuclare, our main objective remains to produce solid clinical evidence and strategize our path toward commercialization. We are particularly excited about the prospect of entering international markets like the United States and Japan, pending regulatory approvals."

Looking ahead, Deepson Bio is poised to initiate pivotal clinical trials in collaboration with several prestigious institutions, including Seoul National University Bundang Hospital and Ewha Womans University Hospitals. The company's planned trials signify an important chapter in clinical research for dementia treatments, indicating a promising future for patients affected by this debilitating condition.

By continually refining their technology and expanding their research capabilities, Deepson Bio aims to make significant contributions to the therapeutic landscape of neurodegenerative disorders. The company is committed to exploring further applications of its ultrasound technology beyond dementia, potentially addressing other complex neurological diseases in the future.

As the global population ages, the demand for effective treatments for dementia and other neurodegenerative conditions continues to escalate, underscoring the importance of innovative solutions like those developed by Deepson Bio. Their recent recognition at the Korea Invention Patent Exhibition not only highlights their achievements but also reaffirms their commitment to advancing medical technology for a healthier tomorrow.